Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): A phase I/II study

Leukemia

Volumn 10, Issue 1, 1996, Pages 43-47

  Wielenga, J J ^a   Vellenga, E ^b   Groenewegen, A ^c   Sonneveld, P ^a   Lowenberg B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Sandoz Ltd   (Netherlands)

Author keywords

Acute myeloid leukemia; Interleukin 3

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; RECOMBINANT INTERLEUKIN 3;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRITIS; ARTICLE; BONE MARROW HYPOPLASIA; BONE PAIN; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; FLUID RETENTION; HEADACHE; HUMAN; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RASH; RELAPSE; REMISSION; THORAX PAIN; THROMBOCYTOPENIA;

EID: 0030034609     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Uhlman DL, Bloomfield CD, Hurd DD, Peterson BA. Prognostic factors at relapse for adults with acute myeloid leukemia. Am J Hematology 1990; 33: 110-116.
2. Minden MD, Till JE, McCulloch EA. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood 1978; 52: 592-600.
3. Lista P, Porcu P, Avanzi GC, Pegorano L. Interleukin-3 enhances the cytotoxic activity of 1-β-D-arabinofuranosylcytosin (Ara-C) on acute meyloblastic leukemia (AML) cells. Br J Haematol 1988; 69: 121-123.
4. Tafuri A, Andreeff M. Kinetic rationale for cytokine induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826-834.
5. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and the myeloid blastic crise of chronic myeloid leukemias. Leukemia 1989; 8: 328-334.
6. Bettelheim P et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700-711.
7. Cannistra SA et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5: 230-238.
8. Vellenga E et al. VP-16-mediated cytotoxicity is modulated by interleukin-3 in a growth factor dependent leukemic cell line. Leukemia 1994; 8: 2060-2064.
9. Metcalf D. The colony stimulating factors: discovery, development and clinical applications. Cancer 1990; 65: 2185-2195.
10. Hoelzer D, Seipelt G, Ganser A. Interleukin-3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease. Semin Hematol 1991; 28: (Suppl. 2): 17-24.
11. Griffin JD et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986; 67: 1448-1453.
12. Delwel R et al. Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 1987; 70: 333-336.
13. Delwel R et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hemopoietic factors in a serum-free culture system. Blood 1988; 72: 1944-1949.
14. Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD. Effects of recombinant IL-3, GM-CSF and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1987; 1: 584-589.
15. Miyauchi J et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987; 70: 657-663.
16. Dorssers L et al. Characterization of a human multilineage colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3. Gene 1987; 55: 115-124.
17. Bot FJ, Dorssers L, Wagemaker G, Löwenberg B. Stimulating spectrum of human recombinant multi-CSF on human marrow precursors: importance of accessory cells. Blood 1988; 71: 1609-1614
18. Ottmann OG et al. Simulation of human hemopoietic progenitor cell proliferation and differentiation by recombinant human interleukin-3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors. Exp Hematol 1989; 17: 191-197.
19. Mazur EM et al. Recombinant gibbon interleukin-3 stimulates megakaryocytic colony growth in vitro from human peripheral blood progenitor cells. J Cell Physiol 1988; 136: 439-446.
20. Leary AG et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hemopoietic stem cells. comparison with interleukin-1 alpha. Blood 1988; 71: 1759-1763.
21. Ogawa M, Clark SC. Synergistic interaction between interleukin-6 and interleukin-3 in support of stem cell proliferation in culture. Blood Cells 1988; 14: 329-337.
22. Rothenberg ME et al. Human eosinophils have prolonged survival, enhanced properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988; 81: 1986-1992.
23. Young DA, Lowe LD, Clark SC. Comparison of the effect of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990; 145: 607-615.
24. Wagemaker G et al. Highly increased production of bone marrow derived blood cells by administration of homologous interleukin-3 to Rhesus monkeys. Blood 1990; 76: 2235-2241.
25. Van Gils FCJM. Interleukin-3 Thesis. Erasmus University Rotterdam, The Netherlands, 1993.
26. Ganser A et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666-676.
27. Bennet JM et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Int Med 1985; 103: 620-625.
28. Löwenberg B et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7: 1268-1274.
29. Keating MJ et al. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 1981; 58: 584-591.
30. Rees JKH, Gray R. Comparison of 1+5 DAT and 3+10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC Ninth AML Trial. Semin Oncol 1987; 14 (Suppl. 1): 32-36.
31. Baudard M et al. Acute myelogenous leukemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82-91.